Evidence map›Paper›PMID 39458989›Full record

ArticlePharmaceuticals (Basel, Switzerland)2024

6-Shogaol Abrogates Parkinson's Disease in Rotenone-Induced Rodents: Based on In Silico Study and Inhibiting TNF-α/NF-κB/IL-1β/MAO-B.

Misbahuddin Rafeeq, Fahad A Al-Abbasi, Muhammad Afzal, Ehssan Moglad, Salwa D Al-Qahtani, Sami I Alzrea, Naif A R Almalki, Faisal Imam, Nadeem Sayyed, Imran Kazmi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Misbahuddin RafeeqDepartment of Pharmacology Faculty of Medicine, Rabigh King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-7219-9149
Fahad A Al-AbbasiDepartment of Biochemistry, Faculty of Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0001-5609-4913
Muhammad AfzalDepartment of Pharmaceutical Sciences, Pharmacy Program, Batterjee Medical College, Jeddah 21442, Saudi Arabia.
Ehssan MogladDepartment of Pharmaceutics, College of Pharmacy, Prince Sattam bin Abdulaziz University, Alkharj 11942, Saudi Arabia.
Salwa D Al-QahtaniDepartment of Medical Laboratory Sciences, College of Applied Medical Sciences, Majmaah University, Al Majmaah 11952, Saudi Arabia.
Sami I AlzreaDepartment of Pharmacology, College of Pharmacy, Jouf University, Aljouf, Sakaka 72341, Saudi Arabia.ORCID 0000-0003-4007-4023
Naif A R AlmalkiDepartment of Biochemistry, Faculty of Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-1142-607X
Faisal ImamDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.ORCID 0000-0003-2285-6806
Nadeem SayyedSchool of Pharmacy, Glocal University, Saharanpur 247121, India.ORCID 0000-0003-0517-4934
Imran KazmiDepartment of Biochemistry, Faculty of Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0003-1881-5219

Funding

King Saud University RSPD2024
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

6-shogaolneuroinflammationneuroprotectiveParkinson’s diseaserotenone

Identifiers

PMID39458989
PMCPMC11510247

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.